Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
AFGC welcomes Domestic Gas Reservation Bill
Beverage facility built to keep the good times rolling
Industries transitioning away from gas, A2EP report released
Six on the shelf: from frozen treats to smoothies & meal kits
58% of food manufacturers report less productivity, research finds
The roles of the vendor and EPCs in the project bidding process
ARC awards $82.5m for new research hubs and training centres
Industrial electricity costs could halve by sharing infrastructure
Seeq and Applied Computing partner on industrial AI for energy operations
ARENA opens Round 3 of Solar Sunshot with $250m available